HC Wainwright Reiterates “Buy” Rating for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the company. Barclays decreased their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. Royal Bank Of Canada reissued a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Wall Street Zen lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sangamo Therapeutics presently has an average rating of “Hold” and a consensus price target of $4.50.

Sangamo Therapeutics Stock Up 13.3%

Shares of NASDAQ:SGMO opened at $0.58 on Tuesday. The business has a fifty day moving average of $0.57 and a two-hundred day moving average of $1.00. The stock has a market cap of $135.70 million, a P/E ratio of -1.49 and a beta of 1.19. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $6.44 million for the quarter, compared to analysts’ expectations of $7.90 million. Sangamo Therapeutics had a negative return on equity of 345.98% and a negative net margin of 124.61%. On average, equities analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new position in shares of Sangamo Therapeutics in the 4th quarter valued at approximately $2,316,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Sangamo Therapeutics in the 4th quarter valued at approximately $1,744,000. GSA Capital Partners LLP grew its stake in shares of Sangamo Therapeutics by 2,962.2% in the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock valued at $634,000 after purchasing an additional 934,649 shares during the last quarter. Acuta Capital Partners LLC purchased a new position in shares of Sangamo Therapeutics in the 4th quarter valued at approximately $755,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Sangamo Therapeutics in the 4th quarter valued at approximately $722,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.